In vivo delivery of RNAi with lipid-based nanoparticles.

RNA interference (RNAi) technology represents a fundamentally new category of treatments for human disease by addressing targets that are traditionally considered undruggable with existing medicines. The major challenge for RNAi-based therapy is the delivery system that meets human therapeutic needs. Therefore, engineering vectors with good delivery efficiency and safety profile is an intense area of research. Lipid-based nanoparticles for RNAi have yielded successful advances in vivo and to an extent in clinical trials. In this review, we discuss the barriers in developing lipid-based nanoparticles for in vivo RNAi and different strategies to overcome them. Rational designs that address safety concerns and ensure effective delivery will aid the translation of engineered lipid-based nanoparticles toward the clinic in the foreseeable future.

[1]  Z. Paroo,et al.  Biodistribution of phosphodiester and phosphorothioate siRNA. , 2004, Bioorganic & medicinal chemistry letters.

[2]  P. Cullis,et al.  Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. , 1996, Biochemistry.

[3]  Leaf Huang,et al.  Immunostimulation of dendritic cells by cationic liposomes , 2006, Molecular membrane biology.

[4]  K. Maruyama,et al.  Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.

[5]  J. Ruysschaert,et al.  Cationic liposomal lipids: from gene carriers to cell signaling. , 2008, Progress in lipid research.

[6]  P. Cullis,et al.  Roles of lipid polymorphism in intracellular delivery. , 2001, Advanced drug delivery reviews.

[7]  P. Cullis,et al.  Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids. , 1996, Biochemistry.

[8]  M. Frank,et al.  The role of complement in inflammation and phagocytosis. , 1991, Immunology today.

[9]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Marsh,et al.  Lipid membranes with grafted polymers: physicochemical aspects. , 2003, Biochimica et biophysica acta.

[11]  F. Szoka,et al.  Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. , 2001, Bioconjugate chemistry.

[12]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[13]  John Maraganore,et al.  A status report on RNAi therapeutics , 2010, Silence.

[14]  I. Maclachlan,et al.  Stabilized plasmid-lipid particles: a systemic gene therapy vector. , 2002, Methods in enzymology.

[15]  Leaf Huang,et al.  Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. , 2009, Biochimica et biophysica acta.

[16]  A. Judge,et al.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  P. Cullis,et al.  Stabilized Plasmid–Lipid Particles: Pharmacokinetics and Plasmid Delivery to Distal Tumors following Intravenous Injection , 2000, Journal of drug targeting.

[18]  Mark E. Davis,et al.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.

[19]  V. Torchilin,et al.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.

[20]  Leaf Huang,et al.  Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. , 2005, Molecular pharmaceutics.

[21]  Y. Quinn,et al.  New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.

[22]  Han-Oh Park,et al.  Chemical modification of siRNAs to improve serum stability without loss of efficacy. , 2006, Biochemical and biophysical research communications.

[23]  Y. Omidi,et al.  Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity , 2007, Journal of drug targeting.

[24]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Leaf Huang,et al.  Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  N. Yamazaki,et al.  CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[27]  F. Szoka,et al.  Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.

[28]  D. Weissman,et al.  Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 31 , 2004, The Journal of Immunology.

[29]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[30]  Jonathan Preall,et al.  RNAi: RISC Gets Loaded , 2005, Cell.

[31]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[32]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[33]  B. Demeneix,et al.  In vivo siRNA delivery to the mouse hypothalamus shows a role of the co-chaperone XAP2 in regulating TRH transcription. , 2008, Methods in molecular biology.

[34]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[35]  A. Klibanov,et al.  Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[37]  Douglas S. Conklin,et al.  Gene expression: RNA interference in adult mice , 2002, Nature.

[38]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[39]  A. Pasquinelli,et al.  Genes and Mechanisms Related to RNA Interference Regulate Expression of the Small Temporal RNAs that Control C. elegans Developmental Timing , 2001, Cell.

[40]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[41]  F. Chang,et al.  Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Helmut Thissen,et al.  Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins. , 2002, Biomaterials.

[43]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[44]  L. Palmer,et al.  Stabilized plasmid-lipid particles: construction and characterization , 1999, Gene Therapy.

[45]  Jianzhu Chen,et al.  A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery , 2009, Molecular pharmaceutics.

[46]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[47]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[48]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[49]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[50]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[51]  V. Kim,et al.  MicroRNA maturation: stepwise processing and subcellular localization , 2002, The EMBO journal.

[52]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Needham,et al.  Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). , 1995, Biophysical journal.

[54]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[55]  G. Gregoriadis,et al.  Liposome-mediated DNA vaccination: the effect of vesicle composition. , 2001, Vaccine.

[56]  H Akita,et al.  Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid , 2007, Gene Therapy.

[57]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[58]  M. Conese,et al.  Biodistribution and transgene expression with nonviral cationic vector/DNA complexes in the lungs , 2000, Gene Therapy.

[59]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[60]  K. Matthay,et al.  Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[61]  Leaf Huang,et al.  Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[62]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[63]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[64]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Jeffrey L. Wrana,et al.  Distinct endocytic pathways regulate TGF-β receptor signalling and turnover , 2003, Nature Cell Biology.

[66]  J. Wolff,et al.  Breaking the bonds: non-viral vectors become chemically dynamic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  Yu-cheng Tseng,et al.  Lipid-based systemic delivery of siRNA. , 2009, Advanced drug delivery reviews.

[68]  D. Fischer,et al.  Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[69]  Leaf Huang,et al.  Effects of Polyethyleneglycol Chain Length and Phospholipid Acyl Chain Composition on the Interaction of Polyethyleneglycol-phospholipid Conjugates with Phospholipid: Implications in Liposomal Drug Delivery , 1996, Pharmaceutical Research.

[70]  M. Hope,et al.  Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid , 2005, Journal of Pharmacology and Experimental Therapeutics.

[71]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[72]  T. Segura,et al.  siRNA applications in nanomedicine. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[73]  T. Ishida,et al.  Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[74]  Leaf Huang,et al.  Lipid-protamine-DNA-mediated antigen delivery. , 2005, Current drug delivery.

[75]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[76]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[77]  S. Hirota,et al.  Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. , 2000, International journal of pharmaceutics.

[78]  D. Dean,et al.  Progress and prospects: nuclear import of nonviral vectors , 2010, Gene Therapy.

[79]  T. Allen,et al.  Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. , 2004, Pharmacological research.

[80]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[81]  M. Ladanyi,et al.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. , 2009, The Journal of clinical investigation.

[82]  S. Gruner,et al.  Lipid polymorphism: the molecular basis of nonbilayer phases. , 1985, Annual review of biophysics and biophysical chemistry.

[83]  W. Shen,et al.  Isolation of variants of chinese hamster ovary cells with abnormally low levels of GSH: Decreased ability to cleave endocytosed disulfide bonds , 1991, Journal of cellular physiology.

[84]  P. Opolon,et al.  Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. , 2002, Biochemical and biophysical research communications.

[85]  Yadollah Omidi,et al.  Toxicogenomics of Non-viral Vectors for Gene Therapy: A Microarray Study of Lipofectin- and Oligofectamine-induced Gene Expression Changes in Human Epithelial Cells , 2003, Journal of drug targeting.

[86]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[88]  J. Vorhies,et al.  Synthetic vs. natural/biodegradable polymers for delivery of shRNA-based cancer therapies. , 2009, Methods in molecular biology.

[89]  O. Boerman,et al.  INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES , 2006, Drug Metabolism and Disposition.

[90]  P. Cullis,et al.  On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids , 2001, Gene Therapy.

[91]  Yu-cheng Tseng,et al.  Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[92]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[93]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[94]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[95]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[96]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[97]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[99]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[100]  R. Langer,et al.  Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis , 2005, The journal of gene medicine.

[101]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[102]  P. Cullis,et al.  Stabilization of bilayer structure for unsaturated phosphatidylethanolamines by detergents. , 1982, Biochimica et biophysica acta.

[103]  B. Bachhawat,et al.  The effect of surface charges of liposomes in immunopotentiation , 1984, Bioscience reports.

[104]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[105]  Jaroslav Pelisek,et al.  Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[106]  D. Rao,et al.  siRNA vs. shRNA: similarities and differences. , 2009, Advanced drug delivery reviews.

[107]  S. Andò,et al.  Characteristics and biodistribution of cationic liposomes and their DNA complexes. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[108]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[109]  Leaf Huang,et al.  Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. , 2007, Molecular immunology.

[110]  M. Bally,et al.  Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). , 1997, The Journal of pharmacology and experimental therapeutics.

[111]  M. Baker.  RNA interference: Homing in on delivery , 2010, Nature.

[112]  K. McCoy,et al.  Defective antigen processing correlates with a low level of intracellular glutathione , 1996, European journal of immunology.

[113]  Simon W. Jones,et al.  MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. , 2007, Molecular bioSystems.

[114]  F. Szoka,et al.  Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes* , 2003, Journal of Biological Chemistry.